Checkpoint Therapeutics (NASDAQ:CKPT) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a report released on Monday morning, Benzinga reports. They currently have a $34.00 price objective on the stock.

Checkpoint Therapeutics Stock Down 0.5 %

Shares of Checkpoint Therapeutics stock opened at $2.06 on Monday. The stock’s 50-day simple moving average is $1.77 and its 200-day simple moving average is $1.94. Checkpoint Therapeutics has a 52 week low of $1.30 and a 52 week high of $3.62. The company has a market capitalization of $73.52 million, a price-to-earnings ratio of -0.74 and a beta of 1.13.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its earnings results on Friday, May 10th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.04. On average, equities analysts expect that Checkpoint Therapeutics will post -1.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. grew its stake in Checkpoint Therapeutics by 9.4% in the third quarter. B. Riley Wealth Advisors Inc. now owns 49,150 shares of the company’s stock worth $84,000 after purchasing an additional 4,205 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Checkpoint Therapeutics by 92.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,174 shares of the company’s stock worth $26,000 after purchasing an additional 5,375 shares in the last quarter. Choreo LLC bought a new position in Checkpoint Therapeutics in the fourth quarter worth approximately $44,000. Magnus Financial Group LLC bought a new stake in Checkpoint Therapeutics during the 4th quarter valued at $55,000. Finally, Lindbrook Capital LLC bought a new stake in Checkpoint Therapeutics during the 1st quarter valued at $62,000. Institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.